Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes Mellitus in Obese
Conditions
Brief summary
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. 2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.
Detailed description
Either Pioglitazone or Placebo Pioglitazone will be administered during this study in this Type 2 Diabetic population with Heart Failure to examine if there are any beneficial effects on diastolic and systolic function. Myocardial blood flow (MBF) is measured using a PET scan, then participants will be randomized to pioglitazone or a placebo to examine the effects of the study drug on the effects on the systolic and diastolic function of the heart. In addition, myocardial insulin sensitivity change will be measured as well as myocardial fat content. The ratio of ATP: PCr will also be measured.
Interventions
DRUGPioglitazone
Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
DRUGPlacebo
Placebo for Pioglitazone
Sponsors
The University of Texas Health Science Center at San Antonio
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Neither the participant nor the investigator knows what treatment is given
Intervention model description
double-blind placebo controlled, randomized clinical trial
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 30-70 years 4. Body Mass Index (BMI) of 27.5-40kg/m² 5. HbA1c of 6.5 to 10% 6. Blood pressure of less than or equal to 145/65mmHg 7. eGFR greater than 45 ml/min/1.73m² 8. Subject must have HFpEF (EF \> 50% by ECHO screening) 9. NYHA class II-III heart failure 10. Only T2D patients treated with diet/exercise, metformin, sulfonylurea, metformin/SU, DPP4i or insulin will be studied. 11. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional \[4 weeks\] after the end of study participation. 12. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.
Exclusion criteria
1. Subjects with history of osteoporosis or proliferative diabetic retinopathy 2. Subjects with Heart failure due to restrictive or infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular heart disease, etc. will be excluded 3. Patients with symptomatic coronary artery disease. 4. Subjects with significant change in diuretic management during the month prior to screening (defined by doubling of diuretic dose, or addition of another HF medication). 5. Subjects treated with a GLP-1 RA or thiazolidinedione. 6. Subjects treated with a SGLT2i 7. Pregnancy or lactation 8. Known allergic reactions to components of the study interventions. 9. Any metal plates, parts, screws, shrapnel, pins in body, or cardiac (heart) pacemaker
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Systolic function | Baseline and 6-months post treatment (approximately 24 weeks) | Measurement of change in systolic function of the heart using cardiac MRI |
| Change in Diastolic function | Baseline and 6-months post treatment (approximately 24 weeks) | Measurement of change in diastolic function of the heart using cardiac MRI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Myocardial insulin sensitivity | Baseline and 6-months post treatment (approximately 24 weeks) | Measurement of change in Free Plasma Glucose (FPG) in blood plasma |
| Myocardial fat content | Baseline and 6-months post treatment (approximately 24 weeks) | Measurement of change in myocardial fat content |
| PCr:ATP ratio | Baseline and 6-months post treatment (approximately 24 weeks) | Measurement of change in PCr:ATP ratio |
Countries
United States
Contacts
Primary ContactSivaram Neppala, MD
Backup ContactAndrea Hansis-Diarte, MPH
Outcome results
None listed